The effect of preoperative gemcitabine and nab-Paclitaxel compared to historical controls on RO surgical rate in patients with resectable pancreas cancer.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 24 Mar 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Capecitabine; Fluorouracil
Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Therapeutic Use
Acronyms GAP

01 Jul 2020 Status changed to discontinued, as per results published in the Annals of Surgical Oncology
02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
02 Jun 2015 Status changed from recruiting to completed, according to abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO 2015).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com